Skip to main content
SpringerLink
Log in

Cheap AMD treatment blocked by drug company

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. General Medical Council

References

  1. Cohen D. Why have UK doctors been deterred from prescribing Avastin? BMJ : 1 Apr 2015. Available from: URL: http://dx.doi.org/10.1136/bmj.h1654

    Google Scholar 

  2. Cohen D. Attacks on publicly funded trials: what happens when industry does not want to know the answer. BMJ : 1 Apr 2015. Available from: URL: http://dx.doi.org/10.1136/bmj.h1701

    Google Scholar 

  3. Cohen D. GMC is criticised for refusing to disclose reasons behind its advice to support prescribing for Lucentis rather than Avastin for wet AMD. Internet Document : 13 Apr 2015. Available from: URL: http://dx.doi.org/10.1136/bmj.h1981

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cheap AMD treatment blocked by drug company. PharmacoEcon Outcomes News 726, 3 (2015). https://doi.org/10.1007/s40274-015-2051-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2051-8

Search

Navigation